The recent surge in capital into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and complex drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the potential for game-changing treatments and substantial returns is undeniable, the linked risks are also notable. Many of